Fate Therapeutics (FATE) Interest Expenses (2012 - 2026)

Fate Therapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $116.6 million for Q1 2026.

• Quarterly Interest Expenses fell 10.27% year-over-year to $116.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.6 million (down 10.27% YoY) and the FY2025 annual result came in at $388.0 million, up 7.15% from the prior year.
• Interest Expenses was $116.6 million for Q1 2026 at Fate Therapeutics, up from $43.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $362.1 million in Q4 2024 and bottomed at $10.9 million in Q2 2025.
• A 5-year average of $138.5 million and a median of $123.3 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses soared 312.74% — and 2025, when it tumbled 92.98%.
• Fate Therapeutics' Interest Expenses stood at $296.2 million in 2022, then climbed by 9.36% to $324.0 million in 2023, then gained by 11.77% to $362.1 million in 2024, then slumped by 88.09% to $43.1 million in 2025, then surged by 170.29% to $116.6 million in 2026.
• Business Quant data shows FATE's Interest Expenses at $116.6 million in Q1 2026, $43.1 million in Q3 2025, and $10.9 million in Q2 2025.